In contrast to the triple-negative scenario, where recent advances with immune checkpoint inhibitors have established immunotherapy as a viable strategy in both the neoadjuvant and metastatic settings, the addition of immunotherapy to HER-2-positive breast cancer has not yielded satisfactory or statistically significant results [23, 24]. The gene discussed is ERBB2; the disease is breast carcinoma.